All News

Viral/Non-Viral Vectors

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome
5 December 2023
Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome
Two female pediatric patients with
FDA Investigating ‘Serious Risk’ of Secondary Malignancy Linked to BCMA- or CD19-Directed CAR-T Immunotherapies
29 November 2023
FDA Investigating ‘Serious Risk’ of Secondary Malignancy Linked to BCMA- or CD19-Directed CAR-T Immunotherapies
FDA investigates T cell malignancy
Sernova’s Hemophilia A Program Receives Orphan Drug and Rare Pediatric Disease Designations from FDA
28 November 2023
Sernova’s Hemophilia A Program Receives Orphan Drug and Rare Pediatric Disease Designations from FDA
Sernova has announced that the
Positive Clinical Results in Myotubular Myopathy Demonstrate Impact on Respiratory and Motor Functions Amidst Severe Challenges
23 November 2023
Positive Clinical Results in Myotubular Myopathy Demonstrate Impact on Respiratory and Motor Functions Amidst Severe Challenges
Clinical results of a gene
POPULAR NEWS ITEMS
Image
4 December 2023

20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry

Image
6 December 2023

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

Image
5 December 2023

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome

First Patient Enrolled in AskBio’s Phase I Trial for Multiple System Atrophy-Parkinsonian Type (MSA-P) Gene Therapy
22 November 2023
First Patient Enrolled in AskBio’s Phase I Trial for Multiple System Atrophy-Parkinsonian Type (MSA-P) Gene Therapy
AskBio has announced that the
Yposkesi Launches AAVelocity ‘Plug-and-Play’ AAV Platform
7 November 2023
Yposkesi Launches AAVelocity ‘Plug-and-Play’ AAV Platform
Yposkesi launches AAVelocityTM, a ‘plug-and-play’
Cellectis and AstraZeneca Forge Innovative Partnership to Pioneer Next-Generation Therapeutics
1 November 2023
Cellectis and AstraZeneca Forge Innovative Partnership to Pioneer Next-Generation Therapeutics
Cellectis announces its collaboration with
Verve and Lilly’s Partnership Expands to Include Verve’s in vivo Gene Editing Programs
1 November 2023
Verve and Lilly’s Partnership Expands to Include Verve’s in vivo Gene Editing Programs
Verve and Lilly's partnership expands
Load more News
RECOMENDED TOPICS
Allogeneic
Autologous
CAR-X
Cell Therapy
Cell-Based IO
Gene Editing
Gene Therapy
NKx
Stem Cells
Tissue Engineering
Viral/Non-Viral Vectors
POPULAR NEWS ITEMS
Image

20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry

Image

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

Image

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome